Skip to main content
. 2008 Sep 19;105(39):14867–14872. doi: 10.1073/pnas.0807146105

Fig. 1.

Fig. 1.

Immortalized HMEC expressing oncogenic ras undergo EMT in a serum-rich environment. (A) Growth curves of vHMEC expressing Ha-rasV12 or control vector in the absence or presence of 0.5% or 10% serum. Arrows indicate time at which serum was added. (B) Phase contrast (10×) and immunofluorescence photomicrographs (63×) of vHMEC-ras cells grown in their original concentration of serum (0.5% and 10%, first and second columns, respectively) or after they were switched to no serum (10 → 0, third column). (C) Immunoblot analysis of fibronectin (Fn), N-cadherin (N-cad), and E-cadherin (E-cad) on cell lysates prepared from parental vHMEC (par), vHMEC-vector (vec), vHMEC-ras (ras), vHMEC-ras0.5 (0.5), and vHMEC-ras10 (10) cells. (D) Transwell motility assay depicting migration of cells toward MEGM + 10% FBS as a chemoattractant for 48 h.